DE69637130D1 - Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren - Google Patents

Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren

Info

Publication number
DE69637130D1
DE69637130D1 DE69637130T DE69637130T DE69637130D1 DE 69637130 D1 DE69637130 D1 DE 69637130D1 DE 69637130 T DE69637130 T DE 69637130T DE 69637130 T DE69637130 T DE 69637130T DE 69637130 D1 DE69637130 D1 DE 69637130D1
Authority
DE
Germany
Prior art keywords
insulin
immunoreactive
diabetes mellitus
interact
dependent diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69637130T
Other languages
English (en)
Other versions
DE69637130T2 (de
Inventor
Leonard Harrison
Margo Honeyman
George Rudy
Andrew Lew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN1239A external-priority patent/AUPN123995A0/en
Priority claimed from AUPN5172A external-priority patent/AUPN517295A0/en
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Application granted granted Critical
Publication of DE69637130D1 publication Critical patent/DE69637130D1/de
Publication of DE69637130T2 publication Critical patent/DE69637130T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
DE69637130T 1995-02-20 1996-02-20 Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren Expired - Fee Related DE69637130T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPN123995 1995-02-20
AUPN1239A AUPN123995A0 (en) 1995-02-20 1995-02-20 Immunointeractive molecules
AUPN517295 1995-09-04
AUPN5172A AUPN517295A0 (en) 1995-09-04 1995-09-04 Immunointeractive and immunotherapeutic molecules
PCT/AU1996/000085 WO1996026218A1 (en) 1995-02-20 1996-02-20 Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)

Publications (2)

Publication Number Publication Date
DE69637130D1 true DE69637130D1 (de) 2007-07-26
DE69637130T2 DE69637130T2 (de) 2008-02-21

Family

ID=25644867

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637130T Expired - Fee Related DE69637130T2 (de) 1995-02-20 1996-02-20 Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren

Country Status (9)

Country Link
US (2) US6818217B1 (de)
EP (2) EP0815136B1 (de)
JP (1) JP3778936B2 (de)
AT (1) ATE364701T1 (de)
CA (1) CA2213301C (de)
DE (1) DE69637130T2 (de)
ES (1) ES2289751T3 (de)
HK (1) HK1004949A1 (de)
WO (1) WO1996026218A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525784A1 (de) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
US7361331B2 (en) 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US7422747B2 (en) 1997-10-07 2008-09-09 Loma Linda University Transgenic plant-based vaccines
US6777546B2 (en) 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
SE9704451D0 (sv) * 1997-11-28 1997-11-28 Diamyd Therapeutics Ab New method and compositions for the treatment of autoimmune diseases
AU2205099A (en) * 1997-12-23 1999-07-12 Alexion Pharmaceuticals, Inc. Chimeric proteins for the treatment of diabetes
US6982323B1 (en) 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
DE69930249T2 (de) * 1998-04-22 2006-12-07 Loma Linda University, Loma Linda Verfahren und materialien zur vorbeugung und behandlung von autoimmunkrankheiten
WO2001030378A1 (en) * 1999-10-22 2001-05-03 The Walter And Eliza Hall Institute Of Medical Research A method of prophylaxis and treatment
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
AU2003300681A1 (en) * 2002-10-02 2004-05-04 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
US20050250691A1 (en) * 2004-05-10 2005-11-10 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US20050209138A1 (en) * 2004-03-19 2005-09-22 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
JP2010525049A (ja) * 2007-04-24 2010-07-22 ダイアミド セラピューティクス アーベー 自己免疫疾患及び癌を治療する薬剤及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569792A (en) * 1984-06-14 1986-02-11 Eli Lilly And Company Anti-diabetic compounds
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
DK0572478T3 (da) * 1991-02-22 2006-01-16 Inst Medical W & E Hall HBGAD- og HIGAD-polypeptider og nukleinsyre og anvendelse heraf til diagnostik og behandling af GAD-autoantigen-associerede sygdomme
EP0585356A1 (de) 1991-05-15 1994-03-09 Zymogenetics, Inc. Klonierung und expression des humanen glutamiksaeuredekarboylase-autoantigens aus dem inselorgan
RU2036592C1 (ru) 1991-08-16 1995-06-09 Моисей Михайлович Лернер Устройство для распределения предметов на технологические потоки
CZ342492A3 (en) * 1991-11-26 1993-06-16 Lilly Co Eli Derivatives of tri-arginine insulin, process of their preparation and a pharmaceutical composition in which said derivatives are comprised
DE59305396D1 (de) * 1992-12-02 1997-03-20 Hoechst Ag Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
ES2318847T3 (es) * 1992-12-03 2009-05-01 The Regents Of The University Of California Metodos y reactivos mejorados para el diagnostico y el tratamiento de diabetes y del sindrome de stiff man.
US5547847A (en) 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes
WO1996001846A1 (en) 1994-07-08 1996-01-25 Trustees Of Dartmouth College Proinsulin peptide compounds for detecting and treating type i diabetes
US6509165B1 (en) * 1994-07-08 2003-01-21 Trustees Of Dartmouth College Detection methods for type I diabetes

Also Published As

Publication number Publication date
EP0815136A4 (de) 2001-02-07
US7455984B2 (en) 2008-11-25
WO1996026218A1 (en) 1996-08-29
EP1849870A1 (de) 2007-10-31
DE69637130T2 (de) 2008-02-21
EP0815136B1 (de) 2007-06-13
EP0815136A1 (de) 1998-01-07
CA2213301C (en) 2010-01-26
US6818217B1 (en) 2004-11-16
ES2289751T3 (es) 2008-02-01
JP3778936B2 (ja) 2006-05-24
JPH11500719A (ja) 1999-01-19
CA2213301A1 (en) 1996-08-29
HK1004949A1 (en) 1998-12-18
ATE364701T1 (de) 2007-07-15
US20020142004A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
DE69637130D1 (de) Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
DK228190D0 (da) Rajgraespollenallergen
DE3886060D1 (de) Vorläuferprotein des APC-Polypeptids, dafür codierende DNA und diagnostische Verwendung der DNA und des Proteins.
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
CA2124953A1 (en) Peptides related to prion proteins
NO930440L (no) Tri- og tetravalente monospesifikke antigen-bindingsproteiner
DE69333673D1 (de) Epitope von Stress Proteinen
UA42040C2 (uk) Поліпептид, спосіб діагностики інсулінозалежного цукрового діабету (iddm), що розвинувся або що розвивається (варіанти), набір для діагностики iddm (варіанти), препарат для запобігання або лікування iddm, фармацевтична композиція для профілактики або лікування iddm
DE69019190D1 (de) Pankreatische Isletzellen-Antigene, erhalten durch molekulare Klonierung.
HUP9901688A2 (hu) A diabétesz kezelésére szolgáló, humán hősokk protein 60-ból származó új peptidek, készítmények, eljárások és kitek
PT929669E (pt) Antigenios derivados das filagrinas e a sua utilizacao para o diagostico da poliartrite reumatoide
DE69432449D1 (de) Verfahren zur Herstellung von hydrophoben Polypeptiden, Proteinen und Peptiden
DE3879085D1 (de) Snrnp-a-antigen und fragmente davon.
DE69230614T2 (de) Protein-s polypeptide und deren verwendungen
ATE277176T1 (de) Faltende proteine
NO304233B1 (no) Polypeptid og sett for diagnostisering av insulinavhengig diabetes mellitus samt fremstilling av slikt materiale
DK222390A (da) Heparin-bindende proteiner, dna'er, der koder for saadanne proteiner, fremgangsmaade til fremstilling af proteinerne same farmaceutiske praeparater indeholdende disse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee